Clinical Trial Update: Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Besponsa (inotuzumab ozogamicin) for younger patients with CD22-positive B-acute lymphoblastic leukemia or B-lymphoblastic l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-acute Lymphoblastic Leukemia
• B-lymphoblastic Lymphoma

Drugs mentioned

• Besponsa (inotuzumab ozogamicin)

Snippet

Sponsor: Children's Oncology Group | Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 2 | Status: RECRUITING